{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:28:31Z","timestamp":1781648911685,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s13555-020-00469-6","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T11:07:03Z","timestamp":1607944023000},"page":"149-160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Real-World Experience and Laboratory Monitoring of Dupilumab in Patients with Moderate to Severe Atopic Dermatitis in a Tertiary Centre"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7934-0806","authenticated-orcid":false,"given":"Firas Constantin","family":"Kreeshan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Al-Janabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard Bruce","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamish John Alexander","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,14]]},"reference":[{"issue":"1","key":"469_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"469_CR2","doi-asserted-by":"publisher","first-page":"e3980","DOI":"10.1371\/journal.pone.0039803","volume":"7","author":"IA Deckers","year":"2012","unstructured":"Deckers IA, McLean S, Linssen S, Mommers M, Van Schayck CP, Sheikh A. Investigating international time trends in the incidence and prevalence of atopic eczema 1990\u20132010: a systematic review of epidemiological studies. PLoS ONE. 2012;7(7):e3980.","journal-title":"PLoS ONE"},{"issue":"6","key":"469_CR3","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jaci.2009.10.009","volume":"124","author":"JA Odhiambo","year":"2009","unstructured":"Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, ISAAC Phase Three Study Group. Global variation in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124(6):1251-8.e23.","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"469_CR4","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","volume":"132","author":"JI Silverberg","year":"2013","unstructured":"Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"469_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1600-065X.2011.01027.x","volume":"242","author":"M Boguniewicz","year":"2011","unstructured":"Boguniewicz M, Leung DY. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233\u201346.","journal-title":"Immunol Rev"},{"issue":"6","key":"469_CR6","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","volume":"130","author":"JK Gittler","year":"2012","unstructured":"Gittler JK, Shemer A, Su\u00e1rez-Fari\u00f1as M, Fuentes-Duculan J, Gulewicz KJ, Wang CQ, et\u00a0al. Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344\u201354.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"469_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.det.2017.02.005","volume":"35","author":"JI Silverberg","year":"2017","unstructured":"Silverberg JI, Kantor R. The Role Of Interleukins 4 and\/or 13 in the pathophysiology and treatment of atopic dermatitis. Dermatol Clin. 2017;35(3):327\u201334.","journal-title":"Dermatol Clin"},{"key":"469_CR8","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","volume":"139","author":"PM Brunner","year":"2017","unstructured":"Brunner PM, Guttman-Yassky E, Leung DYM. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139:S65\u201376.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"469_CR9","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.14888","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et\u00a0al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850\u201378.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"469_CR10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA, Tha\u00e7i D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et\u00a0al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"469_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40257-017-0324-7","volume":"19","author":"I Snast","year":"2018","unstructured":"Snast I, Reiter O, Hodak E, Friedland R, Mimouni D, Leshem YA. Are biologics efficacious in atopic dermatitis? A systematic review and meta-analysis. Am J Clin Dermatol. 2018;19(2):145\u201365.","journal-title":"Am J Clin Dermatol"},{"issue":"24","key":"469_CR12","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et\u00a0al. Two phase 3 trials of dupilumab versus Placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"10086","key":"469_CR13","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, et\u00a0al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303.","journal-title":"Lancet"},{"issue":"5","key":"469_CR14","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"M de Bruin-Weller","year":"2018","unstructured":"de Bruin-Weller M, Tha\u00e7i D, Smith CH, Reich K, Cork MJ, Radin A, et\u00a0al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9). Br J Dermatol. 2018;178(5):1083\u2013101.","journal-title":"Br J Dermatol"},{"key":"469_CR15","unstructured":"Dupixent (dupilumab) 300\u00a0mg solution for injection in preflled syringe and pen: summary of product characteristics. Paris: Sanof-Aventis Groupe. 2019. https:\/\/www.medicines.org.uk\/emc\/product\/8553\/smpc#gref. Accessed 31 Oct 2020."},{"key":"469_CR16","unstructured":"Dupixent\u00ae (dupilumab) injection, for subcutaneous use: US prescribing information. Tarrytown: Regeneron Pharmaceuticals, Inc. 2019. https:\/\/www.regeneron.com\/sites\/default\/files\/Dupixent_FPI.pdf. Accessed 31 Oct 2020."},{"key":"469_CR17","unstructured":"Dupixent (dupilumab). Summary of Product Characteristics. European Medicines Agency. 2017. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dupixent-epar-product-information_en.pdf. Accessed 31 Oct 2020."},{"issue":"5","key":"469_CR18","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1001\/jamadermatol.2018.0183","volume":"154","author":"KJ Mason","year":"2018","unstructured":"Mason KJ, Barker JNWN, Smith CH, Hampton PJ, Lunt M, McElhone K, et\u00a0al. Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR. JAMA Dermatol. 2018;154(5):581\u20138.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"469_CR19","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1111\/bjd.17849","volume":"181","author":"ZZ Yiu","year":"2019","unstructured":"Yiu ZZ, Mason KJ, Barker JN, Hampton PJ, McElhone K, Smith CH, et\u00a0al. A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. Br J Dermatol. 2019;181(6):1265\u201371.","journal-title":"Br J Dermatol"},{"issue":"1","key":"469_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","volume":"10","author":"JM Hanifin","year":"2001","unstructured":"Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M, et\u00a0al. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10(1):11\u20138.","journal-title":"Exp Dermatol"},{"issue":"3","key":"469_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"469_CR22","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/bjd.18041","volume":"181","author":"JC Armario-Hita","year":"2019","unstructured":"Armario-Hita JC, Pereyra-Rodriguez J, Silvestre JF, Ruiz-Villaverde R, Valero A, Izu-Belloso R, et\u00a0al. Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series. Br J Dermatol. 2019;181(5):1072\u20134.","journal-title":"Br J Dermatol"},{"issue":"8","key":"469_CR23","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1111\/jdv.15609","volume":"33","author":"CM Olesen","year":"2019","unstructured":"Olesen CM, Holm JG, N\u00f8rreslet LB, Serup JV, Thomsen SF, Agner T. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre. J Eur Acad Dermatol Venereol. 2019;33(8):1562\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"469_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","volume":"81","author":"S Faiz","year":"2019","unstructured":"Faiz S, Giovannelli J, Podevin C, Jachiet M, Bouaziz JD, Reguiai Z, et\u00a0al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81(1):143\u201351.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"469_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/bjd.18179","volume":"182","author":"LEM de Wijs","year":"2020","unstructured":"de Wijs LEM, Bosma AL, Erler NS, Hollestein LM, Gerbens LAA, Middelkamp-Hup MA, et\u00a0al. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data. Br J Dermatol. 2020;182(2):418\u201326.","journal-title":"Br J Dermatol"},{"issue":"3","key":"469_CR26","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/bjd.17869","volume":"181","author":"B Akinlade","year":"2019","unstructured":"Akinlade B, Guttman-Yassky E, de Bruin-Weller M, Simpson EL, Blauvelt A, Cork MJ, et\u00a0al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459\u201373.","journal-title":"Br J Dermatol"},{"issue":"2","key":"469_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/ijd.14573","volume":"59","author":"C Wang","year":"2020","unstructured":"Wang C, Kraus CN, Patel KG, Ganesan AK, Grando SA. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients\u2019 records. Int J Dermatol. 2020;59(2):253\u20136.","journal-title":"Int J Dermatol"},{"issue":"6","key":"469_CR28","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1111\/bjd.17629","volume":"180","author":"M Tauber","year":"2019","unstructured":"Tauber M, Apoil PA, Richet C, Laurent J, De Bonnecaze G, Mouchon E, et\u00a0al. Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real life practice. Br J Dermatol. 2019;180(6):1551\u20132.","journal-title":"Br J Dermatol"},{"issue":"4","key":"469_CR29","doi-asserted-by":"publisher","first-page":"e12931","DOI":"10.1111\/dth.12931","volume":"32","author":"R Ruiz-Villaverde","year":"2019","unstructured":"Ruiz-Villaverde R, Dominguez-Cruz J, Armario-Hita JC, Martinez-Pilar L, Alcantara-Luna S, Pereyra-Rodriguez JJ. Fifty two week follow-up safety and effectiveness results of dupilumab treatment of moderate-to-severe atopic dermatitis from a retrospective, multicentric series. Dermatol Ther. 2019;32(4):e12931.","journal-title":"Dermatol Ther"},{"key":"469_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.intimp.2017.11.031","volume":"54","author":"Z Ou","year":"2018","unstructured":"Ou Z, Chen C, Chen A, Yang Y, Zhou W. Adverse events of dupilumab in adults with moderate-to severe atopic dermatitis: a meta-analysis. Int Immunopharmacol. 2018;54:303\u201310.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"469_CR31","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaad.2017.03.003","volume":"77","author":"JP Thyssen","year":"2017","unstructured":"Thyssen JP, Toft PB, Halling-Overgaard AS, Gislason GH, Skov L, Egeberg A. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. J Am Acad Dermatol. 2017;77(2):280-286.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"469_CR32","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","volume":"154","author":"AD Treister","year":"2018","unstructured":"Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol. 2018;154(10):1208\u201311.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"469_CR33","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/bjd.18730","volume":"183","author":"LEM de Wijs","year":"2020","unstructured":"de Wijs LEM, Nguyen NT, Kunkeler ACM, Nijsten T, Damman J, Hijnen DJ. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol. 2020;183(4):745\u20139.","journal-title":"Br J Dermatol"},{"issue":"3","key":"469_CR34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/DER.0000000000000481","volume":"30","author":"E Fowler","year":"2019","unstructured":"Fowler E, Silverberg JI, Fox JD, Yosipovitch G. Psoriasiform dermatitis after initiation of treatment with dupilumab for atopic dermatitis. Dermatitis. 2019;30(3):234\u20136.","journal-title":"Dermatitis"},{"issue":"7","key":"469_CR35","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jdcr.2018.05.014","volume":"4","author":"EH Tracey","year":"2018","unstructured":"Tracey EH, Elston C, Feasel P, Piliang M, Michael M, Vij A. Erythrodermic presentation of psoriasis in a patient in treated with dupilumab. JAAD case rep. 2018;4(7):708\u201310.","journal-title":"JAAD case rep"},{"key":"469_CR36","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1111\/ced.13901","volume":"44","author":"G Safa","year":"2019","unstructured":"Safa G, Paumier V. Psoriasis induced by dupilumab therapy. Clin Exp Dermatol. 2019;44:e49\u201350.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"469_CR37","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jaci.2010.11.043","volume":"127","author":"DC Newcomb","year":"2011","unstructured":"Newcomb DC, Boswell MG, Zhou W, Huckabee MM, Goleniewska K, Sevin CM, et\u00a0al. Human TH17 cells express a functional IL-13 receptor and IL-13 attenuates IL-17A production. J allergy Clin Immunol. 2011;127(4):1006-13.e1\u20134.","journal-title":"J allergy Clin Immunol."},{"issue":"5","key":"469_CR38","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/bjd.18031","volume":"181","author":"ZN Willsmore","year":"2019","unstructured":"Willsmore ZN, Woolf RT, Hughes C, Menon B, Kirkham B, Smith CH, et\u00a0al. Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series. B J Dermatol. 2019;181(5):1068\u201370.","journal-title":"B J Dermatol"},{"key":"469_CR39","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1073\/pnas.1416922112","volume":"112","author":"E Guenova","year":"2015","unstructured":"Guenova E, Skabytska Y, Hoetzenecker W, Weindl G, Sauer K, Tham M, et\u00a0al. IL-4 abrogates Th17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. Proc Natl Acad Sci USA. 2015;112:2163\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"469_CR40","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jdcr.2018.10.010","volume":"5","author":"K Flanagan","year":"2019","unstructured":"Flanagan K, Sperling L, Lin J. Drug-induced alopecia after dupilumab therapy. JAAD Case Rep. 2019;5(1):54\u20136.","journal-title":"JAAD Case Rep"},{"key":"469_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000512","author":"JM Carnicle","year":"2020","unstructured":"Carnicle JM, Hendricks AJ, Shi VY. Reactivation of alopecia areata after dupilumab therap for atopic dermatitis. Dermatitis. 2020;. https:\/\/doi.org\/10.1097\/DER.0000000000000512.","journal-title":"Dermatitis."},{"issue":"2","key":"469_CR42","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jdcr.2018.11.007","volume":"5","author":"J Smogorzewski","year":"2019","unstructured":"Smogorzewski J, Sierro T, Compoginis G, Kim G. Remission of alopecia universalis in a patient with atopic dermatitis treated with dupilumab. JAAD Case Rep. 2019;5(2):116\u20137.","journal-title":"JAAD Case Rep."},{"issue":"4","key":"469_CR43","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1111\/jdv.16094","volume":"34","author":"GA Zhu","year":"2020","unstructured":"Zhu GA, Kang KJ, Chen JK, Novoa RA, Brown RA, Chiou AS, et\u00a0al. Inflammatory alopecia in patients on dupilumab: a retrospective cohort study at an academic institution. J Eur Acad Dermatol Venereol. 2020;34(4):e159\u201361.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"469_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/DAD.0b013e3181ef7403","volume":"33","author":"LA Doyle","year":"2011","unstructured":"Doyle LA, Sperling LC, Baksh S, Lackey J, Thomas B, Vleugels RA, et\u00a0al. Psoriatic alopecia\/alopecia areata-like reactions secondary to anti-tumor necrosis factor-\u03b1 therapy: a novel cause of noncicatricial alopecia. Am J Dermatopathol. 2011;33(2):161\u20136.","journal-title":"Am J Dermatopathol"},{"issue":"5","key":"469_CR45","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/bjd.18434","volume":"182","author":"AN Wollenberg","year":"2020","unstructured":"Wollenberg AN, Beck LA, Blauvelt A, Simpson EL, Chen Z, Chen Q, et\u00a0al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2020;182(5):1120\u201335.","journal-title":"Br J Dermatol"},{"key":"469_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/all.14510","author":"I Agache","year":"2020","unstructured":"Agache I, Song Y, Posso M, Alonso-Coello P, Rocha C, Sol\u00e0 I, Beltran J, et al. Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI Biologicals Guidelines. Allergy. 2020;. https:\/\/doi.org\/10.1111\/all.14510.","journal-title":"Allergy."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00469-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13555-020-00469-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-020-00469-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T04:42:54Z","timestamp":1615610574000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13555-020-00469-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,14]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["469"],"URL":"https:\/\/doi.org\/10.1007\/s13555-020-00469-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,14]]},"assertion":[{"value":"5 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}